HRP20191620T1 - Grpr-antagonisti za otkrivanje, dijagnostiku i liječenje grpr-pozitivnog raka - Google Patents
Grpr-antagonisti za otkrivanje, dijagnostiku i liječenje grpr-pozitivnog raka Download PDFInfo
- Publication number
- HRP20191620T1 HRP20191620T1 HRP20191620T HRP20191620T1 HR P20191620 T1 HRP20191620 T1 HR P20191620T1 HR P20191620 T HRP20191620 T HR P20191620T HR P20191620 T1 HRP20191620 T1 HR P20191620T1
- Authority
- HR
- Croatia
- Prior art keywords
- grpr
- antagonist
- antagonist according
- radiolabeled
- radiolabeled grpr
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title claims 22
- 206010028980 Neoplasm Diseases 0.000 title claims 6
- 201000011510 cancer Diseases 0.000 title claims 5
- 238000001514 detection method Methods 0.000 title claims 2
- 238000003745 diagnosis Methods 0.000 title claims 2
- 238000011282 treatment Methods 0.000 title claims 2
- 101150032569 Grpr gene Proteins 0.000 title 1
- 239000002738 chelating agent Substances 0.000 claims 14
- 229910052751 metal Inorganic materials 0.000 claims 10
- 239000002184 metal Substances 0.000 claims 10
- 230000001588 bifunctional effect Effects 0.000 claims 3
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 3
- 102100030671 Gastrin-releasing peptide receptor Human genes 0.000 claims 2
- 101001010479 Homo sapiens Gastrin-releasing peptide receptor Proteins 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 150000002739 metals Chemical class 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 229910052702 rhenium Inorganic materials 0.000 claims 2
- WUAPFZMCVAUBPE-UHFFFAOYSA-N rhenium atom Chemical compound [Re] WUAPFZMCVAUBPE-UHFFFAOYSA-N 0.000 claims 2
- 229910052713 technetium Inorganic materials 0.000 claims 2
- GKLVYJBZJHMRIY-UHFFFAOYSA-N technetium atom Chemical compound [Tc] GKLVYJBZJHMRIY-UHFFFAOYSA-N 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- VILCJCGEZXAXTO-UHFFFAOYSA-N 2,2,2-tetramine Chemical compound NCCNCCNCCN VILCJCGEZXAXTO-UHFFFAOYSA-N 0.000 claims 1
- JHALWMSZGCVVEM-UHFFFAOYSA-N 2-[4,7-bis(carboxymethyl)-1,4,7-triazonan-1-yl]acetic acid Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CC1 JHALWMSZGCVVEM-UHFFFAOYSA-N 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- KSSJBGNOJJETTC-UHFFFAOYSA-N COC1=C(C=CC=C1)N(C1=CC=2C3(C4=CC(=CC=C4C=2C=C1)N(C1=CC=C(C=C1)OC)C1=C(C=CC=C1)OC)C1=CC(=CC=C1C=1C=CC(=CC=13)N(C1=CC=C(C=C1)OC)C1=C(C=CC=C1)OC)N(C1=CC=C(C=C1)OC)C1=C(C=CC=C1)OC)C1=CC=C(C=C1)OC Chemical compound COC1=C(C=CC=C1)N(C1=CC=2C3(C4=CC(=CC=C4C=2C=C1)N(C1=CC=C(C=C1)OC)C1=C(C=CC=C1)OC)C1=CC(=CC=C1C=1C=CC(=CC=13)N(C1=CC=C(C=C1)OC)C1=C(C=CC=C1)OC)N(C1=CC=C(C=C1)OC)C1=C(C=CC=C1)OC)C1=CC=C(C=C1)OC KSSJBGNOJJETTC-UHFFFAOYSA-N 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 241000612152 Cyclamen hederifolium Species 0.000 claims 1
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 claims 1
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims 1
- WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 claims 1
- 125000002015 acyclic group Chemical group 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 229930186364 cyclamen Natural products 0.000 claims 1
- 239000000032 diagnostic agent Substances 0.000 claims 1
- 229940039227 diagnostic agent Drugs 0.000 claims 1
- 210000002249 digestive system Anatomy 0.000 claims 1
- 230000002357 endometrial effect Effects 0.000 claims 1
- 208000023965 endometrium neoplasm Diseases 0.000 claims 1
- 208000015419 gastrin-producing neuroendocrine tumor Diseases 0.000 claims 1
- 201000000052 gastrinoma Diseases 0.000 claims 1
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 230000009826 neoplastic cell growth Effects 0.000 claims 1
- 201000011519 neuroendocrine tumor Diseases 0.000 claims 1
- 125000002524 organometallic group Chemical group 0.000 claims 1
- 230000002611 ovarian Effects 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 125000006850 spacer group Chemical group 0.000 claims 1
- 208000017572 squamous cell neoplasm Diseases 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 210000005166 vasculature Anatomy 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/008—Peptides; Proteins
Claims (19)
1. Radiomarkirani GRPR-antagonist opće formule MC-S-P pri čemu:
M je radiometal i C je metalni kelator koji stabilno veže M ili MC je Tyr- ili prostetska skupina vezana na radiohalogen, pri čemu je M radiohalogen;
S je
razmaknica kovalentno vezana između C i P, pri čemu je S kovalentno pripojen na N-terminus od P; i P je DPhe-Gln-Trp-Ala-Val-Gly-His-CO-NH-CH[CH2-CH(CH3)2]2 (SEQ ID NO: 1).
2. Radiomarkirani GRPR-antagonist prema zahtjevu 1, pri čemu je M odabran od skupine koja se sastoji od 111In, 99mTc, 94mTc, 67Ga, 66Ga, 68Ga, 52Fe, 69Er, 72As, 97Ru, 203Pb, 62Cu, 64Cu, 67Cu, 186Re, 188Re, 86Y, 90Y, 51Cr, 52mMn, 157Gd, 177Lu, 161Tb, 169Yb, 175Yb, 105Rh, 166Dy, 166Ho, 153Sm, 149Pm, 151Pm, 172Tm, 121Sn, 177mSn, 213Bi, 142Pr, 143Pr, 198Au, 199Au, 123I, 124I, 125I i 18F.
3. Radiomarkirani GRPR-antagonist prema zahtjevu 2, pri čemu je M 111In, 177Lu, 67Ga, 68Ga, 99mTc, 186Re ili 188Re.
4. Radiomarkirani GRPR-antagonist prema bilo kojem od zahtjeva 1-3, pri čemu je metalni kelator C metalni kelator za di- i trivalentne metale.
5. Radiomarkirani GRPR-antagonist prema zahtjevu 4, pri čemu je metalni kelator za di- i trivalentne metale DTPA, NOTA, DOTA ili TETA kelator ili njihov derivat, uključujući njihove bifunkcionalne derivate.
6. Radiomarkirani GRPR-antagonist prema zahtjevu 1, pri čemu je metalni kelator C odabran od skupine koja se sastoji od:
7. Radiomarkirani GRPR-antagonist prema zahtjevu 1, pri čemu je metalni kelator C metalni kelator za tehnecij ili renij.
8. Radiomarkirani GRPR-antagonist prema zahtjevu 1, pri čemu je C metalni kelator za radionuklide tehnecija ili renija odabran od skupine koja se sastoji od acikličnog tetraamina, ciklama, PnAO, tetradentatnih kelatora koji sadrže setove donor atoma odabranih od skupine koja se sastoji od P2S2-, N2S2- i N3S-, derivata spomenutih tetradendatnih kelatora, bifunkcionalnih derivata spomenutih tetradendatnih kelatora, HYNIC/ko-ligand-baziranih kelatora i bi- i tridentatnih kelatora koji formiraju organometalne komplekse kroz trikarbonil tehnologiju.
9. Radiomarkirani GRPR-antagonist prema zahtjevu 1, pri čemu je C odabran od skupine koja se sastoji od:
i njihovih bifunkcionalnih derivata.
10. Radiomarkirani GRPR-antagonist prema bilo kojem od zahtjeva 1-9 za uporabu kao lijek.
11. Radiomarkirani GRPR-antagonist prema bilo kojem od zahtjeva 1-9 za uporabu kao dijagnostički ili terapeutski agens za otkrivanje, dijagnostiku ili liječenje primarnog i/ili metastatskog GRPR-pozitivnog raka.
12. Radiomarkirani GRPR-antagonist za uporabu prema zahtjevu 11, pri čemu je rak odabran od raka prostate, raka dojke, raka pluća malih stanica, karcinoma debelog crijeva, gastrointenstinalnih stromalnih tumora, gastrinoma, karcinoma renalnih stanica, neuroendokrinih tumora probavnog sustava i gušterače, tumora skvamoznih stanica jednjaka, neuroblastoma, karcinoma skvamoznih stanica glave i vrata, kao i tumora jajnika, endometrija i gušterače koji pokazuju vaskulaturu povezanu s neoplazijom koja je GRPR-pozitivna.
13. Radiomarkirani GRPR-antagonist za uporabu prema zahtjevu 12, pri čemu je rak humani rak.
14. Dijagnostički i/ili terapeutski sastav, koji sadrži radiomarkirani GRPR-antagonist prema bilo kojem od zahtjeva 1-9, i terapeutski prihvatljivu pomoćnu tvar.
15. Radiomarkirani GRPR-antagonist prema zahtjevu 1, pri čemu je antagonist NeoBOMB-1:
(M-DOTA-(p-aminobenzilamin-diglikolna kiselina)-[DPhe6,His12-CO-NH-CH[CH2-CH(CH3)2]2,des-Leu13,des-Met14] BBN(6-14)).
16. Radiomarkirani GRPR-antagonist prema zahtjevu 15, pri čemu je M 111In, 177Lu, 67Ga, 68Ga.
17. Radiomarkirani GRPR-antagonist prema zahtjevu 1, pri čemu je antagonist NeoBOMB-2:
(M-N4-(p-aminobenzilamin-diglikolna kiselina)-[DPhe6,His12-CO-NH-CH[CH2-CH(CH3)2]2,des-Leu13,des-Met14] BBN(6-14)).
18. Radiomarkirani GRPR-antagonist prema zahtjevu 17, pri čemu je M 99mTC, 186Re ili 188Re.
19. Dijagnostički i/ili terapijski sastav, koji sadrži GRPR-antagonist prema bilo kojem od zahtjeva 15-18, i terapeutski prihvatljivu pomoćnu tvar.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261705513P | 2012-09-25 | 2012-09-25 | |
| PCT/US2013/061712 WO2014052471A1 (en) | 2012-09-25 | 2013-09-25 | Grpr-antagonists for detection, diagnosis and treatment of grpr-positive cancer |
| EP13815181.6A EP2900279B1 (en) | 2012-09-25 | 2013-09-25 | Grpr-antagonists for detection, diagnosis and treatment of grpr-positive cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20191620T1 true HRP20191620T1 (hr) | 2019-12-13 |
Family
ID=49887190
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20191620 HRP20191620T1 (hr) | 2012-09-25 | 2019-09-09 | Grpr-antagonisti za otkrivanje, dijagnostiku i liječenje grpr-pozitivnog raka |
Country Status (19)
| Country | Link |
|---|---|
| US (6) | US9839703B2 (hr) |
| EP (2) | EP2900279B1 (hr) |
| JP (4) | JP6562838B2 (hr) |
| KR (2) | KR102314293B1 (hr) |
| AU (4) | AU2013323596C1 (hr) |
| BR (1) | BR112015006453B1 (hr) |
| CA (2) | CA2886068C (hr) |
| DK (1) | DK2900279T3 (hr) |
| ES (1) | ES2745635T3 (hr) |
| HR (1) | HRP20191620T1 (hr) |
| HU (1) | HUE045724T2 (hr) |
| IL (3) | IL237844B (hr) |
| LT (1) | LT2900279T (hr) |
| MX (1) | MX362675B (hr) |
| PL (1) | PL2900279T3 (hr) |
| PT (1) | PT2900279T (hr) |
| RU (2) | RU2693465C9 (hr) |
| SI (1) | SI2900279T1 (hr) |
| WO (1) | WO2014052471A1 (hr) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10449260B2 (en) * | 2011-07-08 | 2019-10-22 | Theodosia Maina-Nock | Enhanced in vivo targeting of radiolabelled peptides with the means of enzyme inhibitors |
| BR112015006453B1 (pt) * | 2012-09-25 | 2023-10-17 | Advanced Accelerator Applications Usa, Inc. | Antagonista de grpr radiomarcado e composição terapêutica que o compreende |
| EP3015462A1 (en) * | 2014-10-29 | 2016-05-04 | OctreoPharm Schiences GmbH | Enantiopure chelating agents for chelator coupled pharmaceuticals, corresponding preparation method thereof and chelator coupled pharmaceuticals |
| EP3101012A1 (en) | 2015-06-04 | 2016-12-07 | Bayer Pharma Aktiengesellschaft | New gadolinium chelate compounds for use in magnetic resonance imaging |
| WO2018048882A1 (en) | 2016-09-06 | 2018-03-15 | The Research Foundation For The State University Of New York | Positron imaging tomography imaging agent composition and method for bacterial infection |
| EP3544964B1 (en) | 2016-11-28 | 2020-06-17 | Bayer Pharma Aktiengesellschaft | High relaxivity gadolinium chelate compounds for use in magnetic resonance imaging |
| PT3568205T (pt) | 2017-01-12 | 2023-10-26 | Radiomedix Inc | Tratamento de células de cancro que sobrexpressam recetores de somatostatina com a utilização de derivados de ocreótido quelado a radioisótopos |
| EP3863686A1 (en) | 2018-10-12 | 2021-08-18 | Advanced Accelerator Applications International S.A. | Pharmaceutical composition comprising a radiolabeled gprp antagonist and a surfactant |
| AU2019469641A1 (en) * | 2018-11-13 | 2021-07-01 | Provincial Health Services Authority | Radiolabeled bombesin-derived compounds for in vivo imaging of gastrin-releasing peptide receptor (GRPR) and treatment of GRPR-related disorders |
| AU2019382881A1 (en) | 2018-11-23 | 2021-05-20 | Bayer Aktiengesellschaft | Formulation of contrast media and process of preparation thereof |
| TW202123976A (zh) * | 2019-09-16 | 2021-07-01 | 義大利商先進艾斯雷特應用（義大利）公司 | 穩定濃縮之放射性醫藥組合物 |
| TW202123975A (zh) * | 2019-09-17 | 2021-07-01 | 義大利商先進艾斯雷特應用（義大利）公司 | 放射性標記grpr拮抗劑之方法及其套組 |
| CN114728089A (zh) * | 2019-09-24 | 2022-07-08 | 诺华股份有限公司 | 用作治疗诊断剂的经放射性标记的grpr拮抗剂 |
| CN114845742A (zh) * | 2019-12-19 | 2022-08-02 | 慕尼黑工业大学 | 用于癌症成像和治疗的经改性的grpr拮抗剂肽 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5019647A (en) | 1988-05-24 | 1991-05-28 | Merck & Co., Inc. | Gastrin releasing peptide antagonist |
| US4943561A (en) | 1988-11-28 | 1990-07-24 | Merck & Co., Inc. | Gastrin releasing peptide antagonist |
| US5028692A (en) | 1989-04-25 | 1991-07-02 | Merck & Co., Inc. | Gastrin releasing peptide antagonist |
| IE903958A1 (en) | 1989-11-06 | 1991-05-08 | Erba Carlo Spa | Reduced irreversible bombesin antagonists |
| JPH07505865A (ja) | 1992-02-07 | 1995-06-29 | メレルダウファーマスーティカルズ インコーポレイテッド | ボンベシンのフェニルアラニン類似体類 |
| US5620955A (en) | 1993-06-18 | 1997-04-15 | Peptide Technologies Corporation | Bombesin receptor antagonists and uses thereof |
| US6545125B1 (en) | 1997-11-18 | 2003-04-08 | Chugai Seiyaku Kabushiki Kaisha | Compounds with antitumor activity |
| CA2526556C (en) | 2003-07-24 | 2012-09-25 | Bracco Imaging S.P.A. | Stable radiopharmaceutical compositions and methods for their preparation |
| EP2100900A1 (en) * | 2008-03-07 | 2009-09-16 | Universitätsspital Basel | Bombesin analog peptide antagonist conjugates |
| JP2014500262A (ja) | 2010-11-22 | 2014-01-09 | ピラマル イメージング ソシエテ アノニム | 放射線治療のための１７７ルテチウム標識されたボンベシン類似体 |
| US10449260B2 (en) * | 2011-07-08 | 2019-10-22 | Theodosia Maina-Nock | Enhanced in vivo targeting of radiolabelled peptides with the means of enzyme inhibitors |
| BR112015006453B1 (pt) * | 2012-09-25 | 2023-10-17 | Advanced Accelerator Applications Usa, Inc. | Antagonista de grpr radiomarcado e composição terapêutica que o compreende |
-
2013
- 2013-09-25 BR BR112015006453-1A patent/BR112015006453B1/pt active IP Right Grant
- 2013-09-25 WO PCT/US2013/061712 patent/WO2014052471A1/en active Application Filing
- 2013-09-25 AU AU2013323596A patent/AU2013323596C1/en active Active
- 2013-09-25 KR KR1020207034970A patent/KR102314293B1/ko active IP Right Grant
- 2013-09-25 MX MX2015003772A patent/MX362675B/es active IP Right Grant
- 2013-09-25 RU RU2015115529A patent/RU2693465C9/ru active
- 2013-09-25 RU RU2019119378A patent/RU2019119378A/ru unknown
- 2013-09-25 DK DK13815181.6T patent/DK2900279T3/da active
- 2013-09-25 US US14/431,096 patent/US9839703B2/en active Active
- 2013-09-25 EP EP13815181.6A patent/EP2900279B1/en active Active
- 2013-09-25 PT PT138151816T patent/PT2900279T/pt unknown
- 2013-09-25 EP EP19170067.3A patent/EP3536347A1/en active Pending
- 2013-09-25 ES ES13815181T patent/ES2745635T3/es active Active
- 2013-09-25 CA CA2886068A patent/CA2886068C/en active Active
- 2013-09-25 CA CA3114832A patent/CA3114832A1/en active Pending
- 2013-09-25 SI SI201331585T patent/SI2900279T1/sl unknown
- 2013-09-25 LT LT13815181T patent/LT2900279T/lt unknown
- 2013-09-25 JP JP2015534625A patent/JP6562838B2/ja active Active
- 2013-09-25 KR KR1020157007572A patent/KR102190005B1/ko active IP Right Grant
- 2013-09-25 HU HUE13815181A patent/HUE045724T2/hu unknown
- 2013-09-25 PL PL13815181T patent/PL2900279T3/pl unknown
-
2015
- 2015-03-19 IL IL237844A patent/IL237844B/en active IP Right Review Request
-
2017
- 2017-11-20 US US15/817,776 patent/US20180133349A1/en not_active Abandoned
- 2017-12-28 IL IL256649A patent/IL256649B/en active IP Right Grant
-
2018
- 2018-06-21 AU AU2018204513A patent/AU2018204513C1/en active Active
-
2019
- 2019-06-04 JP JP2019104379A patent/JP6997135B2/ja active Active
- 2019-08-16 AU AU2019216714A patent/AU2019216714B2/en active Active
- 2019-09-09 HR HRP20191620 patent/HRP20191620T1/hr unknown
- 2019-09-24 US US16/580,990 patent/US11083805B2/en active Active
-
2020
- 2020-07-26 IL IL276300A patent/IL276300A/en unknown
-
2021
- 2021-03-26 AU AU2021201914A patent/AU2021201914A1/en active Pending
- 2021-07-23 US US17/383,577 patent/US20210346529A1/en active Pending
- 2021-07-23 US US17/383,550 patent/US20210346528A1/en active Pending
- 2021-07-23 US US17/383,567 patent/US20220008568A1/en active Pending
- 2021-09-22 JP JP2021154188A patent/JP7358430B2/ja active Active
-
2023
- 2023-07-13 JP JP2023115231A patent/JP2023126440A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20191620T1 (hr) | Grpr-antagonisti za otkrivanje, dijagnostiku i liječenje grpr-pozitivnog raka | |
| ES2440919T3 (es) | Nuevos polipéptidos con afinidad por HER2 | |
| GEP20237497B (en) | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer | |
| ES2615805T3 (es) | Conjugados de antagonista de péptido análogo de la bombesina | |
| Faintuch et al. | Radiolabeled bombesin analogs for prostate cancer diagnosis: preclinical studies | |
| Barbet et al. | Radiolabeled antibodies for cancer imaging and therapy | |
| CA2643744A1 (en) | Cancer imaging and treatment | |
| HRP20211386T1 (hr) | Sredstva sa visokim afinitetom za ciljano djelovanje na membranski antigen specifičan za prostatu za endoradioterapiju raka prostate | |
| HRP20171291T1 (hr) | Polipeptidi i konjugati klorotoksina i njihove uporabe | |
| Varasteh et al. | The effect of macrocyclic chelators on the targeting properties of the 68Ga-labeled gastrin releasing peptide receptor antagonist PEG2-RM26 | |
| CA2841238C (en) | Enhanced in vivo targeting of radiolabelled peptides with the means of enzyme inhibitors | |
| Sabahnoo et al. | New small 99mTc-labeled peptides for HER2 receptor imaging | |
| PH31049A (en) | Bicyclopolyazamacrocy clophosphonic acid complexesfor use as radiopharmaceuticals. | |
| Alves et al. | Pyrazolyl conjugates of bombesin: a new tridentate ligand framework for the stabilization of fac-[M (CO) 3]+ moiety | |
| Santos-Cuevas et al. | Design, preparation, in vitro and in vivo evaluation of 99mTc-N2S2-Tat (49–57)-bombesin: a target-specific hybrid radiopharmaceutical | |
| SI2535358T1 (en) | Anti-cadherin antibody, labeled with radioactive metal | |
| Welling et al. | Infection detection in mice using 99mTc-labeled HYNIC and N2S2 chelate conjugated to the antimicrobial peptide UBI 29-41 | |
| ES2957460T3 (es) | Composición farmacéutica de un compuesto que contiene nitrógeno o una sal del mismo, o complejo de metal de los mismos | |
| EP2935335B1 (en) | New polypeptides | |
| Fragogeorgi et al. | Spacer Site Modifications for the Improvement of the in Vitro and in Vivo Binding Properties of 99mTc-N3S-X-Bombesin [2− 14] Derivatives | |
| Knetsch et al. | [68Ga] NS3-RGD and [68Ga] Oxo-DO3A-RGD for imaging αvβ3 integrin expression: synthesis, evaluation, and comparison | |
| Solomon et al. | 99mTc (CO) 3+ labeled domain I/II-specific anti-EGFR (scFv) 2 antibody fragment for imaging EGFR expression | |
| Klasen et al. | AAZTA5-squaramide ester competing with DOTA-, DTPA-and CHX-A ″-DTPA-analogues: Promising tool for 177Lu-labeling of monoclonal antibodies under mild conditions | |
| Lim et al. | Preclinical pharmacokinetic, biodistribution, imaging and therapeutic efficacy of 177Lu-Labeled glycated bombesin analogue for gastrin-releasing peptide receptor-positive prostate tumor targeting | |
| Griffiths | Radiochemistry of therapeutic radionuclides |